These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32020213)

  • 1. An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation.
    Sheng W; Geng J; Li L; Shang Y; Jiang M; Zhen Y
    Oncol Rep; 2020 Mar; 43(3):851-863. PubMed ID: 32020213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
    Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
    Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
    Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
    Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
    Zheng YB; Shang BY; Li Y; Zhen YS
    Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Recombinant and Reconstituted Novel Albumin-Lidamycin Conjugate Shows Lasting Tumor Imaging and Intensively Enhanced Therapeutic Efficacy.
    Li L; Hu L; Zhao CY; Zhang SH; Wang R; Li Y; Shao RG; Zhen YS
    Bioconjug Chem; 2018 Sep; 29(9):3104-3112. PubMed ID: 30105903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
    Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
    Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.
    Guo XF; Zhu XF; Yang WC; Zhang SH; Zhen YS
    PLoS One; 2014; 9(3):e92986. PubMed ID: 24664246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Construction of energized fusion protein consisting of epidermal growth factor receptor oligopeptide ligand and lidamycin and its antitumor activity].
    Guo XF; Zhong GS; Miao QF; Zhen YS
    Ai Zheng; 2009 Jun; 28(6):561-8. PubMed ID: 19635191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
    Chen J; Ouyang ZG; Zhang SH; Zhen YS
    Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation.
    Liu WJ; Liu XJ; Li L; Li Y; Zhang SH; Zhen YS
    Cancer Immunol Immunother; 2014 Dec; 63(12):1261-72. PubMed ID: 25164878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.
    Xu J; Liu XJ; Li L; Zhang SH; Li Y; Gao RJ; Zhen YS
    Oncotarget; 2015 Sep; 6(28):26322-34. PubMed ID: 26314845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a genetically engineered chimeric apoprotein consisting of sequences derived from lidamycin and neocarzinostatin.
    Jiang W; Shang B; Li L; Zhang S; Zhen Y
    Anticancer Drugs; 2016 Jan; 27(1):24-8. PubMed ID: 26457548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
    Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
    Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
    Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
    Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding capability of the enediyne-associated apoprotein to human tumors and constitution of a ligand oligopeptide-integrated protein.
    Cai L; Chen H; Miao Q; Wu S; Shang Y; Zhen Y
    J Biotechnol; 2009 Oct; 144(2):142-50. PubMed ID: 19737585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice.
    Zhong G; Zhang S; Li Y; Liu X; Gao R; Miao Q; Zhen Y
    Cancer Lett; 2010 Sep; 295(1):124-33. PubMed ID: 20303650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.
    He S; Zhao C; Tao H; Sheng W; Gao R; Liu X; Zhen Y
    Drug Deliv; 2022 Dec; 29(1):1243-1256. PubMed ID: 35416106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.